



HIV experts on the decision to use early ART for prevention in France: are we there yet?

Bertrand Lebouché, Kim Engler, Joseph Josy Lévy, Gimore, Bruno Spire, Willy Rozenbaum, Jean-Pierre Routy

► To cite this version:

Bertrand Lebouché, Kim Engler, Joseph Josy Lévy, Gimore, Bruno Spire, et al.. HIV experts on the decision to use early ART for prevention in France: are we there yet?. *Retrovirology*, 2012, 9 (Suppl 1), pp.P95. inserm-00701407

HAL Id: inserm-00701407

<https://www.hal.inserm.fr/inserm-00701407>

Submitted on 25 May 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



POSTER PRESENTATION

Open Access

HIV experts on the decision to use early ART for prevention in France: are we there yet?

Bertrand Lebouché¹, Kim Engler^{1*}, Joseph Josy Lévy², Gimore¹, Bruno Spire³, Willy Rozenbaum⁴, Jean-Pierre Routy¹

From 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)
Marseille, France. 23-25 May 2012

Introduction

The finding that successful antiretroviral therapy (ART) can almost eliminate the risk of heterosexual HIV transmission is the scientific breakthrough of 2011 according to Science Magazine. This potential of ART has generated novel approaches to prevention including "Test and Treat" (T&T). Our qualitative study, drawing on the perspectives of French HIV experts, aims to better understand if, and how, a T&T approach might be applied in France and to generally learn more about concerns raised by prevention with early ART.

Materials and methods

In 2011, 19 French HIV experts participated in a semi-structured interview on implementing T&T in France. Expertise was typically defined on the basis of contribution to the 2010 French ART guidelines (Rapport Yeni 2010). Participants' HIV expertise included clinical care, epidemiology, virology, and community activism. Interviews lasted an hour, on average, and explored opinions on T&T, who, how and whether to test and treat, and what public health discourses and evaluations should accompany it. Analyses of interview content pertaining to who or whether to treat early for prevention are presented here. A content analysis of the transcribed interviews was supported by the software Atlas.ti version 5.2.

Results

The decision to treat earlier than current guidelines recommend (CD4 >500) was generally associated with uncertainties and involved weighing the risks and benefits, whether potential or known, primarily in terms of patient health, the risk of transmission, patient choice,

population health and/or cost. Perspectives on each of these aspects varied as did experts' position on treating early for prevention.

Conclusions

Despite ART-based HIV prevention's status as evidence based medicine (EBM), French experts had uncertainties about early preventive treatment of HIV-infection which often translated into a weighing of benefits and risks to varying effect. Our findings suggest fostering a culture of dialogue and debate between care providers, community organizations and recipients of care on the complex considerations of implementing strategies of ART as prevention in France can help translate EBM into improvements in health and new HIV guidelines towards the eradication of HIV.

Author details

¹McGill University Health Centre, Montreal, Canada. ²Université du Québec à Montréal, Canada. ³INSERM-SESSTIM UMR912, Marseille, France. ⁴Hôpital Saint-Louis, Paris, France.

Published: 25 May 2012

doi:10.1186/1742-4690-9-S1-P95

Cite this article as: Lebouché et al.: HIV experts on the decision to use early ART for prevention in France: are we there yet? *Retrovirology* 2012 **9**(Suppl 1):P95.

* Correspondence: kimcengler@gmail.com

¹McGill University Health Centre, Montreal, Canada

Full list of author information is available at the end of the article